Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Eli Lilly and Company (NYSE:LLY) had its target price boosted by equities researchers at Berenberg Bank from $1,050.00 to $1,135.00 in a research note issued to investors on Monday,MarketScreener reports. The firm presently has a “hold” rating on the stock. Berenberg Bank’s price target would suggest a potential upside of 3.30% from the stock’s current price.

Several other equities research analysts have also recently weighed in on LLY. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research note on Tuesday, May 26th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. Bank of America raised their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,230.89.

Eli Lilly and Company Price Performance

LLY stock opened at $1,098.78 on Monday. The stock has a market capitalization of $1.03 trillion, a price-to-earnings ratio of 39.10, a PEG ratio of 1.20 and a beta of 0.53. The firm’s 50-day moving average price is $1,016.10 and its two-hundred day moving average price is $1,017.13. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the stock. Spire Wealth Management raised its holdings in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after purchasing an additional 592 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the period. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after acquiring an additional 5,595 shares during the period. Finally, Stonebridge Capital Advisors LLC boosted its position in Eli Lilly and Company by 318.1% during the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock valued at $8,026,000 after acquiring an additional 8,003 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.